AMALFI - ACTIVE MONITORING FOR ATRIAL FIBRILLATION
We are pleased to announce that we have now recruited over 5000 participants into the study, which means that recruitment is now closed. We would like to say an enormous thank you to both the GP Practices and all their patients who have kindly volunteered to take part and made AMALFI work so well - your contributions are hugely appreciated.
The AMALFI study has been designed and is run by researchers at the University of Oxford's Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and the Division of Cardiovascular Medicine, which are world-leading centres for this type of work.
The study is led by Professor Louise Bowman and Professor Barbara Casadei and involves cardiology and General Practice specialists as well as partnership work with many other local doctors, nurses and healthcare professionals.
This study will look at the possible benefits of screening people using a new Zio Patch monitor to detect atrial fibrillation. Half of the people in this study will wear the patch and half will not, so we can compare the Zio Patch to the usual medical care people receive on the NHS. The patch is used just once and worn continuously for two weeks.
Results regarding the presence or absence of AF and other clinically relevant findings will be sent to GPs who will then discuss any changes in treatment that might be needed. The study team will continue to monitor each participant's medical record for 5 years to see what happens to them during this time and whether the screening has made a difference.
AMALFI has been designed by the University of Oxford, who run the study independently of any funders. The funding itself comes through the NHS funded Biomedical Research Centre and the National Institute for Health and Care Research and the British Heart Foundation with additional support from iRhythm, who donated the Zio Patches free of charge.
